Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF)

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left">Complications</td><td class="align_center">All (<i>n</i> = 1438)</td><td class="align_center">Furosemide plus metolazone (<i>n</i> = 466)</td><td class="align_center">Furosemide (<i>n</i> = 972)</td><td class="align_center"><i>P</i></td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left">Death (%)</td><td class="align_center">320 (22.3)</td><td class="align_center">97 (20.8)</td><td class="align_center">223 (22.9)</td><td class="align_center">0.364</td></tr><tr><td class="align_left">Re-hospitalization (%)</td><td class="align_center">378 (26.3)</td><td class="align_center">113 (24.2)</td><td class="align_center">265 (27.3)</td><td class="align_center">0.224</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Distribution of death and re-hospitalization across different categories of diuretic usages.</div>

Critical Care Research and Practice

tab2

Table 2

Table 2: Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF) 